Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients

3 minute read

Published: Wednesday, October 12, 2022 at 2:43 pm

Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer.